Header

UZH-Logo

Maintenance Infos

Differential influence of vemurafenib and dabrafenib on patients’ lymphocytes despite similar clinical efficacy in melanoma


Schilling, B; Sondermann, W; Zhao, F; Griewank, K G; Livingstone, E; Sucker, A; Zelba, H; Weide, B; Trefzer, U; Wilhelm, T; Loquai, C; Berking, C; Hassel, J; Kähler, K C; Utikal, J; Al Ghazal, P; Gutzmer, R; Goldinger, S M; Zimmer, L; Paschen, A; Hillen, U; Schadendorf, D; Dermatologic Cooperative Oncology Group (2014). Differential influence of vemurafenib and dabrafenib on patients’ lymphocytes despite similar clinical efficacy in melanoma. Annals of Oncology, 25(3):747-753.

Abstract

In this study, we demonstrate that vemurafenib but not dabrafenib reduces peripheral lymphocyte counts in melanoma patients while both agents show similar clinical efficacy. Within the lymphocyte compartment, vemurafenib selectively decreases circulating CD4+ T cells and changes their phenotype and function. This indicates that selective BRAFi need to be assessed individually for immunomodulatory effects, especially, when planning combinations with immunotherapies

Abstract

In this study, we demonstrate that vemurafenib but not dabrafenib reduces peripheral lymphocyte counts in melanoma patients while both agents show similar clinical efficacy. Within the lymphocyte compartment, vemurafenib selectively decreases circulating CD4+ T cells and changes their phenotype and function. This indicates that selective BRAFi need to be assessed individually for immunomodulatory effects, especially, when planning combinations with immunotherapies

Statistics

Citations

Dimensions.ai Metrics
39 citations in Web of Science®
40 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

27 downloads since deposited on 18 Oct 2018
10 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:National licences > 142-005
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Health Sciences > Hematology
Health Sciences > Oncology
Uncontrolled Keywords:T cells; dabrafenib; lymphocytes; melanoma; treatment; vemurafenib
Language:English
Date:1 March 2014
Deposited On:18 Oct 2018 14:44
Last Modified:15 Apr 2021 14:48
Publisher:Oxford University Press
ISSN:0923-7534
OA Status:Hybrid
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:https://doi.org/10.1093/annonc/mdt587
PubMed ID:24504444

Download

Hybrid Open Access

Download PDF  'Differential influence of vemurafenib and dabrafenib on patients’ lymphocytes despite similar clinical efficacy in melanoma'.
Preview
Content: Published Version
Language: English
Filetype: PDF (Nationallizenz 142-005)
Size: 465kB
View at publisher